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Summary
Analysing the genomic data of pathogens with the help of next-generation sequencing 
(NGS) is an increasingly important part of disease outbreak investigations and helps 
guide responses. While this technology has already been successfully employed to 
elucidate and control disease outbreaks, wider implementation of NGS also depends 
on its cost-effectiveness. COMPARE – short for ‘Collaborative Management Platform 
for detection and Analyses of (Re-) emerging and foodborne outbreaks’ – is a major 
project, funded by the European Union, to develop a global platform for sharing and 
analysing NGS data and thereby improve the rapid identification, containment and 
mitigation of emerging infectious diseases and foodborne outbreaks. This article 
introduces the project and presents the results of a review of the literature, composed 
of previous relevant cost–benefit and cost-effectiveness analyses. The authors 
also outline the implications for a methodological framework to assess the cost-
effectiveness of COMPARE and similar systems.
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Introduction
Analysing the genomic data of pathogens is an increasingly 
important part of disease outbreak investigations and helps 
guide responses (1, 2). The most advanced group of methods 
for performing whole-genome sequencing of pathogens, 
next-generation sequencing (NGS), enables researchers to 
generate ‘complete genomic information from the isolate 
or sample, independent of both the sector (public health, 
veterinary health, food safety), and the type of pathogen 
(viruses, bacteria, parasites)’ (3). The outputs of NGS 
(sequence data) ‘provide one common language that can 
be exchanged and compared between laboratories and over 
time’ (3), and can be combined with contextual information, 
such as clinical, microbiological, or epidemiological data. 
The impact of NGS on microbiology is considered to 
have been ‘revolutionary’ (1), with applications of NGS 
ranging from infectious disease diagnostics and hospital 
infection-control surveillance programmes, to investigating 
community outbreaks and predicting antibiotic resistance 
through the identification of known resistance genes. A 
number of recent studies have highlighted the importance 
of NGS for surveillance, tracking diseases, and identifying 
outbreaks (1, 4, 5, 6, 7, 8, 9). NGS is also widely used in 
research studies and increasingly applied as a supplement 
for clinical diagnostics and surveillance.
However, the costs of implementing NGS in routine 
diagnostics and surveillance remain high in comparison to 
the mainly phenotypic testing currently in use. The costs 
involved in implementing NGS include direct and recurrent 
costs associated with producing the data, as well as 
investment costs associated with building and running the 
infrastructure for sharing and analysing the large amount of 
data produced through NGS.
COMPARE – short for Collaborative Management 
Platform for detection and Analyses of (Re-) emerging and 
doi: 10.20506/rst.36.1.2631
312 Rev. Sci. Tech. Off. Int. Epiz., 36 (1)
foodborne outbreaks – is a major project to develop a global 
platform for sharing and analysing NGS data. Started at 
the beginning of 2015, COMPARE is funded by Horizon 
2020, the European Union’s (EU) research and innovation 
programme. It is a collaboration between 28 European 
partners – including leading institutions in the field of 
emerging epidemics and foodborne outbreaks – and will run 
across a total span of five years. COMPARE aims to facilitate 
the early identification and control of relevant outbreaks 
and the correct identification of the potential source(s), 
resulting in considerable savings for the European primary 
and secondary food industry, as well as reduced illness 
for consumers. In addition, early detection and control of 
potentially notifiable disease outbreaks in European farm 
animals are expected to reduce control costs, as well as the 
consequences of trade restrictions (3).
After introducing the project, this article presents the results 
of a literature review of previous relevant cost–benefit and 
cost-effectiveness analyses, and outlines the implications for 
a methodological framework to assess the cost-effectiveness 
of COMPARE and similar systems. This framework will be 
developed and applied during the project’s implementation.
The surge in genomic data and 
the COMPARE system
Whole-genome sequencing allows the entire DNA profile of 
pathogens to be mapped out at one time. For this purpose, 
NGS – like older sequencing technologies – begins with 
the collection and extraction of DNA from a sample. Then, 
‘random DNA fragments are created that contain adapter 
sequences that are complementary to platform-specific 
PCR and sequencing primers. DNA is fragmented, and 
additional processing (e.g. end-repair, A-tailing, ‘barcoding’) 
is completed. [For viruses], PCR amplification of the library 
is needed before sequencing’ (10). The library is then 
sequenced using one of several NGS platforms available.
Replacing first-generation platforms, which used Sanger-
based chemistries and capillary-based instruments, NGS 
technologies involve the parallel sequencing of millions 
of DNA fragments at the same time. The technological 
advances of NGS have led to a sharp drop in the costs of 
DNA sequencing, accompanied by a massive surge in output 
data, which is expected to continue rising to unprecedented 
levels in the coming years (3). Given the large amount of 
data produced by NGS, in the future it will be essential to 
ensure that the information is comparable, to allow it to be 
rapidly searched and analysed.
A number of open-access databases are already in place to 
facilitate the sharing of genomic data. These focus on either 
specific pathogens or specific sectors. For example, the 
Global Initiative on Sharing All Influenza Data (GISAID) 
gathers the sequence data of influenza viruses from 
outbreaks around the world (11) and from other influenza 
sequence databases (12), while the Genome Trakr Network 
in the United States collects and shares genomic data from 
foodborne pathogens. However, with COMPARE, a single 
global platform enables the open sharing of genomic 
information across sectors, countries and pathogen types. 
Equally importantly, the project aims at harmonising 
the methods used by scientists, authorities, doctors and 
organisations around the world to collect samples, generate 
genome sequencing data and carry out risk assessments. 
Figure 1 illustrates the key elements of COMPARE.
A diverse range of stakeholders are involved in COMPARE. 
They include some who act as data providers, others who 
are primarily information users, and many who are likely to 
function as both (3). Users include professionals working in 
public health, food safety, animal health and wildlife, who 
are involved at various levels of research. Public authorities 
and private companies are also expected to use and benefit 
from the system. Key elements of the COMPARE project 
include (3, 13):
– Risk-assessment models and risk-based strategies, which 
guide and structure sample and data collection for NGS-
based analyses to enhance the capacity to detect potential 
disease outbreaks. As part of the research conducted 
since COMPARE began, an inventory of existing sampling 
protocols has been developed to map the type of samples 
that are currently recommended for known diseases in the 
public and animal health sectors.
– Harmonised standards and analytical workflows for sample 
processing and sequencing, which generate high-quality NGS 
data in combination with relevant meta-data for pathogen 
detection and typing across sample types, pathogens and 
domains. Since the start of the project, an inventory of 
commonly used protocols with respect to the collection, 
handling, transport and storage of samples has been created. 
Pipelines for sampling processes before sequencing were 
also developed and initial laboratory operating procedures 
have been prepared.
– Analytical workflows for generating actionable information, 
which allow sequence- and meta-data to be interpreted 
and used when taking decisions in frontline diagnostics, 
foodborne-pathogen surveillance, outbreak detection, and 
epidemiological analysis. To date, a database of reference 
genomes, covering some of the most important foodborne 
pathogens of public health relevance, has been constructed, 
based on publicly available genomes.
– The data and information platform, which provides the 
technical backbone for the elements previously described, 
enabling the rapid sharing and analysis of pathogen 
genomics data. It is intended to be a portal to enable 
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users to report their data sets to the system and query, 
analyse and visualise COMPARE data, global public data of 
relevance and connected external data resources. A number 
of informatics tools have already been launched, including 
COMPARE Data Hubs and a Cloud environment providing 
a selection of bioinformatics tools.
– A risk communication toolbox, which supports the 
development of communication messages about findings, 
outbreaks and new opportunities discovered through 
COMPARE. The toolbox is aimed at stakeholders directly 
or indirectly involved in risk communication.
The final key element of COMPARE is research into its cost-
effectiveness, which aims, among other things, to identify 
the important elements in calculating the costs and benefits 
of COMPARE and similar systems, and to conduct related 
cost-effectiveness case studies.
Towards a framework for 
assessing the cost-effectiveness 
of the COMPARE system
As described above, and for the purpose of such case 
studies, COMPARE may be defined as a system for pathogen 
identification using NGS, with harmonised methods and 
a centralised data hub. To assess the cost-effectiveness of 
this type of system, a methodological framework must be 
defined before research can be conducted on its costs and 
benefits. The elements of such a framework include the:
– perspective of the analysis
– time frame of the analysis
– unit of effectiveness
– baseline
– cost and benefit types.
While these elements are essential for any cost-effectiveness 
or cost–benefit analysis, there is a high degree of variation 
in the specific approaches taken (14, 15). Therefore, as a 
basis for developing a suitable methodological framework, 
a literature review was conducted. It first targeted 
methodological guidance documents and meta-analyses 
of economic analyses conducted in the four key sectors 
covered by COMPARE (human health, food safety, animal 
health and wildlife). Secondly, it focused on previous cost–
benefit and cost-effectiveness analyses of current systems 
for pathogen identification and outbreak prevention, 
including those that use NGS, in these four sectors. The 
aim was to identify best practice as reflected in the guidance 
documents, and to review the methodological framework 
applied in practical cases. 
RA: Risk analysis
Fig. 1 
Key elements of COMPARE (Collaborative Management Platform for detection and Analyses of [Re-] emerging and foodborne outbreaks)
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Relevant articles, reports and studies were identified 
through search engines and specialised databases and 
journals. A series of search term combinations were used, 
containing the keywords ‘next-generation sequencing’, 
‘costs’, ‘benefits’, ‘cost-effectiveness analysis’, ‘cost–benefit 
analysis’, ‘molecular typing’, ‘pathogen’, ‘food’, ‘pathogen 
identification’, etc. In total, 105 documents were selected 
for further screening for their relevance. Based on this 
process, eight specific cost-effectiveness and cost–benefit 
studies were retained for in-depth review. The authors also 
identified guidance documents on cost–benefit and cost-
effectiveness analysis (15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 
25), and included them in the review, where relevant. In the 
following section, they present the results of their review 
concerning the guidance provided, its implementation in 
practical cases, and the conclusions reached to construct 
a cost-effectiveness framework for the COMPARE system. 
More details on the studies identified are provided in 
Table I.
Perspective of the analysis
The chosen point of view from which an analysis is 
conducted determines its scope and which costs and 
benefits are included. While a narrow perspective considers 
only the direct costs of an intervention and the resulting 
benefits for its users, a wider point of view takes into 
account the social, health and economic costs and benefits 
accruing to society as a whole. Among narrow approaches, 
a common perspective adopted in health economics is 
that of the single benevolent decision-maker, whose aim 
is to maximise population health based on the available 
resources. The benefits taken into account are those that 
accrue to the target population; the costs are those provided 
for in the health budget (16).
At the other end of the spectrum, a societal approach 
considers the costs of an intervention that accrue to 
individuals beyond those directly involved, as well as the 
indirect impacts of the policy/programme. For example, 
from this perspective, the opportunity costs and the effect 
on income resulting from health improvements might be 
considered. Most cost-effectiveness guides argue that a 
societal perspective is the appropriate one to adopt in health 
economics, i.e. one which includes all costs, regardless of 
who pays them, and in which resources used by health 
interventions should be valued at the benefit foregone, since 
society cannot then use those resources for their next best 
use (health-related or otherwise) (16). However, a guidance 
document by the World Health Organization (WHO) on 
evaluating the costs and benefits of national surveillance 
and response systems observes that most studies are likely 
to adopt an approach that falls between the decision-maker’s 
narrow perspective and the wider societal one, and that the 
decision on which viewpoint to take will depend upon the 
purpose of the analysis and its intended audience (22).
While a narrow perspective can make sense if decisions 
are taken at a micro level for a detailed patient population 
(e.g. decisions on which chemotherapy a cancer patient 
should receive), the limitations of a narrow perspective 
become more obvious if policies with more diverse 
consequences are being evaluated. In the United Kingdom, 
where a narrow perspective is usually adopted when 
evaluating curative healthcare interventions, there have 
been calls to broaden the perspective when public health 
interventions are assessed. In practice, about 50% of all 
genomic economic evaluations adopt a wider societal 
perspective (26). Among the studies reviewed, half applied a 
narrow perspective (10, 27, 28, 29). The other half adopted 
a wider societal perspective, with some combining the 
narrow and societal approaches, by considering the costs 
of a specific system, and comparing these with the benefits 
accruing to users/patients and the wider societal impacts 
(30, 31, 32, 33). In light of the broad scope of COMPARE 
and its expected far-reaching impacts, a wider societal 
perspective will be taken, possibly by combining specific 
analyses from a narrow perspective with a consideration of 
the wider societal benefits, where possible.
Time frame
Like the choice of perspective, the period covered by an 
analysis has an influence on the inclusion and calculation 
of various costs and benefits. Evaluating an intervention 
for a typical (or reference) year may bias the outcome 
against programmes that take a number of years to start 
providing benefits to their users. On the other hand, a long 
evaluation period is less feasible in practice, due to the 
relatively short time horizon in which health decisions are 
often taken (16). The methodological guidance documents 
reviewed provide several reasons for selecting longer 
time frames for economic evaluations of surveillance and 
response systems (22):
– new features of surveillance and response systems may 
take time to become effective; often there is a gap between 
the time when data is collected and when it is used for 
research/policy purposes
– for surveillance systems designed to detect outbreaks of 
new diseases (which are rare events), the reference period 
should be long enough to allow for the possibility of these 
events to occur
– the reference period should also be long enough for 
estimates of costs and benefits to be independent of 
epidemic-prone diseases with multi-year cycles, and other 
characteristics particular to the reference period.
A WHO guide to cost-effectiveness analysis, Making choices 
in health (16), suggests that generalised cost-effectiveness 
analysis should evaluate interventions over a reference 
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Table I  
Specific cost-effectiveness analyses and other relevant economic evaluations included in this review
Reviewed literature
Perspective  
of the analysis
Time frame Unit of effectiveness Baseline Cost types Benefit types
Assessing the costs 
and cost-effectiveness 
of genomic sequencing 
(10)
Narrow perspective 
(healthcare 
expenditure)
6 months QALYs WGS patients 
before disclosure of 
WGS results/Non-
WGS patients
Costs for gathering informed 
consent, genomic sequencing, 
confirming variants via Sanger 
sequencing, medical care 
costs following disclosure of 
results, patient out-of-pocket 
expenses
A reduction in the number 
of pathogenic and likely 
pathogenic monogenic 
findings for participants, 
improved health-related 
quality of life, early 
identification and prevention 
of potential threats
A qualitative approach 
to measure the 
effectiveness of active 
avian influenza virus 
surveillance with 
respect to its cost: 
a case study from 
Switzerland (11)
Narrow perspective 
(direct surveillance 
costs only)
Reference year 
(2009)
Change in probability 
of transmission of 
HPAI from wild birds to 
poultry, mutation from 
low-pathogenicity avian 
influenza into HPAI in 
poultry, and transmission 
of HPAI to other poultry 
holdings, given a primary 
outbreak
Situation without 
active surveillance 
of avian influenza 
virus
Organisation, materials, 
sample-taking, laboratory 
analysis and labour 
Increased awareness 
and preparedness due to 
surveillance, reduction in 
probability of transmission 
Modelling the cost-
effectiveness of the 
IDSR system: meningitis 
in Burkina Faso (12)
Narrow perspective 
(healthcare provider)
Pre-IDSR 
period 
(1996–2002) 
and post-
IDSR period 
(2003–2007)
Number of cases, deaths 
or sequelae averted
Outbreaks before 
implementation of 
IDSR system
Personnel, transportation 
items, office consumable 
goods, public awareness 
campaigns, laboratory and 
response materials and 
supplies, meningitis case 
management and capital
Cases, deaths or sequelae 
averted
Cost-effectiveness 
analysis of diagnostic 
options for PCP (13)
Narrow perspective 
(healthcare payer 
in developing 
countries)
Unknown (not 
relevant)
Proportion of PCP 
patients successfully 
treated and total 
diagnostic and treatment 
cost per life year gained
Comparison 
between different 
options
Materials and personnel time Correct diagnosis, successful 
treatment, life years gained
An economic evaluation 
of PulseNet (14)
Societal perspective 
(for benefits, 
perspective of public 
health agencies 
towards costs)
Data collected 
between 1994 
and 2009
Reduction in reported 
illnesses
Pre-PulseNet 
situation in states
Programme costs Improved information, 
enhanced industry 
accountability, more rapid 
recalls, cost savings due 
to averted medical costs/
productivity losses, 
improvements in outbreak 
detection, reduction in 
foodborne illness
Study of cost–benefit 
analysis of reference 
laboratories for human 
pathogens (15)
Societal perspective 
(for benefits, 
perspective of EU-RL 
networks and EU 
authorities towards 
costs)
Reference year 
(2013 or 2014)
N/A Comparison 
between different 
coordination 
options in the 
absence of a formal 
EU-wide network 
system for public 
health laboratories
Staff costs, capital equipment 
costs, costs of consumable 
materials, travel and 
accommodation costs, 
shipping costs, subcontracting 
costs and costs of services
Monetary benefits, non-
monetary benefits (for 
members of laboratory 
networks and for society 
over all)
Costs and benefits 
of a subtype-specific 
surveillance system for 
identifying Escherichia 
coli O157:H7 outbreaks 
(16)
Societal perspective 5 years N/A Scenario in the 
absence of a 
subtype-specific 
surveillance system
Labour and equipment costs 
(equipment, laboratory 
scientists, analysing isolates, 
investigating an outbreak, 
present value of outbreak 
costs, annual operating costs)
Economic savings from E. coli 
O157:H7 cases averted 
(medical costs, productivity 
losses, lost lifetime earnings)
An economic evaluation 
of the control of three 
notifiable fish diseases 
in the United Kingdom 
(17)
Societal perspective Net present 
value 
calculated over 
a 10-year time 
horizon
N/A Scenario with no 
or limited disease 
surveillance
Eventual outbreak cost, 
impacts across the industry 
plus social or welfare costs 
to wider society, costs of 
implementing surveillance
Monetary benefits (avoided 
private and social costs of 
potential disease outbreaks)
  EU: European Union
HPAI: highly pathogenic avian influenza
IDSR: integrated disease surveillance 
and response
N/A: not applicable
PCP: pneumocystis pneumonia
QALY: quality-adjusted life year
RL: Reference Laboratory
WGS: whole-genome sequencing
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period of ten years after full implementation. More 
specifically, the analysis should include the start-up costs 
before full implementation, total costs during the ten-
year period, and all health effects that continue to occur 
beyond the reference period. While the feasibility of long 
reference periods also depends on data availability, this 
is a less relevant obstacle for hypothetical and modelling 
studies. When estimating the costs and effects over long 
time horizons, the choice of an appropriate discount rate 
for converting the values to their present worth is of key 
importance, as this may significantly affect results (26). 
While there is a large body of literature in this respect, there 
is no broad consensus across sectors and authors as to which 
discount rates are appropriate in what context. Recent 
general guidance provided by the European Commission 
for assessments in a regulatory context suggests a discount 
rate of 4% if costs and benefits are considered from the point 
of view of society as a whole, and recommends undertaking 
sensitivity analysis of the discount rate when it is applied 
over long time frames (24). The WHO suggests a discount 
rate of 3%, and agrees on the need to conduct sensitivity 
analysis (16), while other guidance documents propose a 
discount rate of 3.5% (21).
A number of different time frames were applied in the 
studies reviewed, from studies focusing on a reference 
period of six months (10) or a year (27, 31) to time frames 
of five to 15 years (30, 32). For other studies, the time 
frame was either unspecified or insignificant, depending on 
the research question. For example, for a cost-effectiveness 
analysis comparing various diagnostic options, the time 
frame was considered to be largely irrelevant as long as the 
comparison was made at the same point in time. 
In the context of COMPARE, the most appropriate reference 
period will be chosen for each of the cost-effectiveness case 
studies. To the extent that specific outbreaks or outbreak 
scenarios will be scrutinised or modelled, the outbreak 
duration would be an appropriate reference period.
Unit of effectiveness
The unit of effectiveness is a measure of a quantifiable 
outcome that is central to the objectives of the programme/
intervention (23). The unit of effectiveness is used to 
calculate the denominator of the cost-effectiveness ratio, 
which in turn allows us to make comparisons between 
various interventions. In health economics, units of 
effectiveness relate to improvements in the length and/or in 
the quality of life. The most commonly used units in the area 
of human health include metrics such as disability-adjusted 
life years (DALYs) and quality-adjusted life years (QALYs) 
(16). Both QALYs and DALYs capture not only the impact 
of diseases on length of life but also multiple dimensions 
indicating the health-related quality of life. While QALYs 
are more popular when evaluating clinical interventions, 
DALYs are more frequently used for evaluating public 
health interventions (34).
In the area of animal health, no similar measure is available, 
and economic analyses often quantify and compare 
outcomes on a monetary basis (e.g. by comparing outbreak 
and response costs with prevention costs). Among the 
studies reviewed, several different units of effectiveness were 
selected, including QALYs (10), the reduction in reported 
illnesses (30), or the number of cases prevented (28). The 
results of the literature review confirm that, while QALYs 
are a standard unit of effectiveness in health economics, 
in practice the units used to measure outcomes vary from 
study to study, reflecting the objectives of the intervention 
being scrutinised and the effects being captured (15). The 
methodological framework for the cost-effectiveness case 
studies will therefore consider the use of QALYs, but other 
outcome measures, such as the number of cases prevented 
or the reduction of outbreak costs, could also be used.
Baseline
Another key element of the methodological framework is the 
baseline – also known as the ‘counterfactual scenario’ or the 
‘comparator’ – against which an intervention is measured. 
By comparing the proposed intervention to an alternative 
scenario, the difference that the intervention makes to a 
given outcome can be measured (22). To fully capture the 
effect of the policy or programme, the outcomes/effects must 
be measured for both the intervention as well as for the 
counterfactual (16). Cellini and Kee (23) define the baseline 
for the analysis as the status quo, or ‘the state of the world 
in the absence of the program or policy’. According to this 
perspective, costs and benefits should only be considered 
in a cost-effectiveness or cost–benefit analysis if they would 
not have occurred in the absence of the intervention. In 
other words, when comparing the intervention to the status 
quo, only the marginal (or incremental) costs and benefits 
should be included in the assessment (23). This approach is 
often taken in cost–benefit analyses and corresponds to the 
EU guidance mentioned earlier (24).
The different baseline scenarios used in the studies 
reviewed reflect the diversity of research methods applied 
across these studies. Some studies compare situations with 
and without surveillance (27, 28, 33), or consider different 
implementation options for a specific intervention (31). 
In one of the studies, researchers exploited the staggered 
adoption of the scrutinised programme (the PulseNet 
Network for Foodborne Disease Surveillance in the United 
States) across different states to estimate the impact of the 
programme. Using this natural experiment, they were able 
to compare states in which the intervention had been put 
in place with those states in which it had not yet been 
adopted (30). Two of the other studies reviewed also used 
the status quo, or absence of a given system or technology, 
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as a baseline scenario, and this approach is also expected to 
be applied for the cost-effectiveness case studies (24, 32).
Types of cost
By definition, cost–benefit and cost-effectiveness analyses 
seek to collect, quantify and assess data about the costs of 
an intervention. Levin (25) defines costs as the value of 
the resources that are given up by society to implement 
the intervention, while Cellini and Kee (23) consider the 
overall costs of a programme as any negative impacts of that 
programme, added to the actual budgetary outlay. The WHO 
guidelines (16) differentiate between the costs of providing 
health interventions and the costs of accessing health 
interventions. Broadly, the categories of costs involved in 
‘providing’ health interventions are the following:
– labour
– capital (such as building space and equipment)
– consumables (such as medical supplies and medication)
– overhead costs (such as electricity, water and 
maintenance).
The costs of ‘accessing’ healthcare interventions accrue to 
patients and their families and consist of the resources used 
and time involved in seeking or obtaining the intervention.
The guidance documents and studies reviewed by the 
authors provide a wide range of cost categorisations, 
including cost categories that correspond to the steps 
involved in an intervention (26) (for a detailed overview, 
refer to Table I).
Differences in the choice of costs (and benefits) included in 
an analysis depend to some extent on the perspective taken. 
From the point of view of the health or veterinary services 
provider or decision-maker, only the direct costs (and 
benefits) of the intervention are considered. For example, a 
focus on programme costs can imply a decision to leave out 
indirect costs, such as the costs borne by other government 
bodies, welfare losses from premature death, and reduced 
quality of life due to illness (30). In contrast, from a societal 
perspective, the wider social, health and economic costs 
(and benefits) have to be taken into account, regardless of 
who pays (or benefits) from those effects (15, 35).
Another factor that contributes to differences in cost 
categorisation across studies is the variety of terms used 
to describe largely similar cost types. In fact, in a majority 
of the studies reviewed, cost types can be grouped into 
the four main cost categories proposed by WHO: labour, 
capital, consumables and overhead costs (16). First, all 
the relevant studies systematically monetised staff time, 
focusing on various categories of personnel, including 
laboratory scientists, healthcare workers, clinicians and 
nurses. Secondly, most of the analyses accounted for 
capital costs representing investments at a single point in 
time, including those related to the construction of the 
building/laboratory and the purchase of equipment. Third, 
some of the studies calculated the cost of consumables, a 
category encompassing materials that are used up as a good 
or service is provided. These could, for example, consist 
of medical supplies or materials required for specimen 
collection and diagnostic test procedures. Overhead costs 
are also considered in several of the studies reviewed, and 
remaining cost types can be grouped under ‘other costs’ 
(depending on the subject area, perspective and level of 
detail used), leaving a total of five broadly applicable cost 
categories.
Benefit types
While ultimately the cost-effectiveness ratio(s) of the 
interventions/alternatives considered are based on one 
or several key measures of outcome, the benefits of the 
intervention are likely to be more far-reaching and numerous 
in practice. When evaluating the costs and benefits of 
national surveillance and response systems, WHO lists the 
following types of benefits that may arise as a result of such 
systems:
– benefits derived from averting cases
– benefits derived from averting deaths
– benefits of fewer social and economic disruptions 
(including disruptions to trade and tourism), when 
epidemics are averted
– social and psychological benefits stemming from less 
apprehension and greater peace of mind when large 
outbreaks of serious infectious diseases are rare or non-
existent (22).
Cellini and Kee (23) suggest identifying and classifying 
benefits (and costs) according to whether they are real 
benefits or merely transfers: direct or indirect, tangible or 
intangible, and financial or social. Based on these categories, 
the authors discuss the following examples of benefit types:
– non-market goods and services, such as social benefits, 
that cannot be readily estimated using market prices and 
budgets
– cost avoidance or cost savings
– time saved
– increased productivity.
Once again, the range of benefits considered depends on the 
perspective taken as well as the type of analysis undertaken 
(i.e. cost-effectiveness or cost–benefit). The reviewed 
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cost–benefit analyses tended to quantify and monetise 
certain key benefits, describing additional benefits 
qualitatively.
An approach for estimating the wider benefits of surveillance 
and detection systems from a more macro perspective 
focuses on the value of information that surveillance and 
detection systems provide. One framework that could be 
used to quantify the value of more and better information 
facilitated through systems such as COMPARE is the so-
called ‘value of information’ (VOI) framework. The VOI 
framework is developed within statistical decision theory 
and has been applied in healthcare and other fields (36, 37, 
38). The key idea behind VOI is that the choice between 
several policy options is distinct from the choice of whether 
or not additional information should be collected by 
financing research, in order to inform the choice between 
these policy options. The value of information is determined 
by assessing to what extent more information can result in 
better decisions that yield a higher expected return (e.g. 
through averted cases, reduced outbreaks and related gains 
in productivity, quality of life, etc.), when compared to 
situations in which there is less information. Information is 
valuable because it reduces the expected costs of uncertainty 
surrounding various policy options.
In addition, surveillance and detection systems may provide 
a sense of safety to populations, or ‘greater peace of mind’, 
as noted before (22). Although this is a difficult element to 
value, it is a relevant benefit from the perspective of policy-
makers, as well as from a welfare economics perspective. 
The feeling of unsafety in countries facing an outbreak can 
be disruptive and unsettling. It is well known that the value 
of safety or avoiding losses can be high, but methods to 
determine these values are currently lacking. An analysis 
of the value of safety and its quantification, as well as the 
development of related methodological approaches, will be 
the focus of the next stage of the cost-effectiveness analysis 
of the COMPARE project.
Conclusion
COMPARE has the potential to bring about significant 
benefits in a variety of areas, including outbreak prevention 
and response, diagnostic improvements, and a resulting 
improvement in the well-being of the population (including 
in regard to their perceived safety). The costs, however, 
are also substantial. The cost-effectiveness case studies 
accompanying the COMPARE project aim to weigh these 
costs against the benefits, by quantifying them in monetary 
terms or through the use of one or more relevant units of 
effectiveness.
Possible case studies include the 2014 outbreak of the 
Ebola virus in western Africa, the outbreak of highly 
pathogenic avian influenza H5N8 virus in 2014, the 2011 
outbreak of Shiga-toxin-producing E. coli in Germany, and 
more general themes, such as Salmonella surveillance. The 
cost-effectiveness studies accompanying the COMPARE 
project will provide insights into the extent to which public 
expenditure on this system, or other pathogen identification 
systems using NGS with harmonised methods and a 
centralised data hub, is justified by its benefits for users and 
society. Moreover, it will serve to guide further refinement 
of such a system, with a view to improving its overall cost-
effectiveness.
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Élaboration d’un cadre d’évaluation du rapport coûts–efficacité 
de COMPARE, plate-forme mondiale d’échange de données de 
séquençage sur les agents pathogènes 
F. Alleweldt, Ş. Kara, A. Osinski, P. van Baal, K. Kellerborg, F.M. Aarestrup 
& M. Koopmans
Résumé
L’analyse des données sur le génome des agents pathogènes grâce au 
séquençage de nouvelle génération (SNG) joue un rôle de plus en plus important 
dans les enquêtes sur les foyers de maladies et contribue à l’élaboration de 
stratégies de réponse. Si cette technologie a été utilisée avec succès pour 
élucider la cause des certains foyers et pour les contrôler, une application plus 
large du SNG dépend également de sa rentabilité. La plate-forme COMPARE 
(plate-forme de gestion collaborative pour la détection et l’analyse des foyers 
émergents et ré-émergents et des toxi-infections alimentaires) est un projet de 
grande envergure financé par l’Union européenne, visant à mettre en place une 
plate-forme mondiale d’échanges et d’analyse des données de séquençage de 
nouvelle génération et à améliorer ainsi l’identification précoce, le confinement 
et l’atténuation des maladies infectieuses émergentes et des foyers de toxi-
infections alimentaires. Les auteurs présentent le projet ainsi que les résultats 
d’une étude bibliographique intégrant des analyses pertinentes coûts–avantages 
et coûts–efficacité réalisées dans le passé. Ils soulignent également les 
enseignements de ces analyses pour l’élaboration d’un cadre méthodologique 
d’évaluation de la relation coûts–efficacité applicable au système COMPARE et à 
d’autres systèmes similaires.
Mots-clés
Agent pathogène – COMPARE – Coûts–avantages – Coûts–efficacité – Détection – 
Informations sur le génome – Séquençage de nouvelle génération – Surveillance.
Concepción de un método para evaluar la relación costo-eficacia 
de COMPARE, dispositivo mundial de intercambio de datos de 
secuencias de patógenos 
F. Alleweldt, Ş. Kara, A. Osinski, P. van Baal, K. Kellerborg, F.M. Aarestrup 
& M. Koopmans
Resumen
El análisis de datos genómicos de los patógenos con ayuda de técnicas de 
secuenciación de próxima generación es un componente cada vez más 
importante de la investigación de brotes infecciosos, que resulta de utilidad para 
guiar las medidas de respuesta. Aunque estas técnicas ya se han utilizado con 
éxito para elucidar y combatir brotes de enfermedad, su aplicación generalizada 
también dependerá de la relación costo-eficacia que ofrezcan. COMPARE 
(acrónimo inglés de «plataforma de gestión colectiva para la detección y análisis 
de brotes (re)emergentes y de transmisión alimentaria») es un vasto proyecto 
financiado por la Unión Europea que apunta a instituir un dispositivo mundial de 
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